Misplaced Pages

K-Ras(G12C) inhibitor 6

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (August 2014) (Learn how and when to remove this message)
K-Ras(G12C) inhibitor 6
Names
Preferred IUPAC name N-{1-piperidin-4-yl}-4-sulfanylbutanamide
Identifiers
CAS Number
3D model (JSmol)
ChemSpider
PubChem CID
UNII
InChI
  • InChI=1S/C17H22Cl2N2O3S/c18-12-3-4-15(14(19)10-12)24-11-17(23)21-7-5-13(6-8-21)20-16(22)2-1-9-25/h3-4,10,13,25H,1-2,5-9,11H2,(H,20,22)Key: ZPXCEHMKUTXHRZ-UHFFFAOYSA-N
SMILES
  • SCCCC(=O)NC1CCN(CC1)C(=O)COC1=CC=C(Cl)C=C1Cl
Properties
Chemical formula C17H22Cl2N2O3S
Molar mass 405.33 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references
Chemical compound

K-Ras(G12C) inhibitor 6 is an irreversible inhibitor of oncogenic K-Ras(G12C), subverting the native nucleotide preference to favour GDP over GTP. Its family of inhibitors allosterically control GTP affinity and effector interactions by fitting inside a "pocket", or binding site, of mutant K-Ras. It is the most frequently mutated oncogene.

Investigators and pathologists previously thought that K-Ras is undruggable. However, Kevan M. Shokat and his colleagues, in the Howard Hughes Medical Institute (HHMI) at the University of California, recently reported a novel discovery of "Achilles heel" on K-RAs, and believed that it has real translational implications for patients with K-RAs mutation.

In recent years, significant research efforts have focused on finding effective inhibitors for the Kras-G12C mutation. For instance, sotorasib (Lumakras) became the first FDA-approved targeted therapy for the treatment of patients with NSCLC harboring the Kras-G12C mutation in 2021. Adagrasib (MRTX849) is another inhibitor that has shown promising results in clinical trials.

References

  1. "Targeting KRAS-G12C | Amgen Oncology". www.amgenoncology.com. Retrieved 2023-12-09.
  2. "Researchers identify new mechanism to target 'undruggable' cancer gene". www.sciencedaily.com. Retrieved 2017-01-17.
  3. "Sotorasib is First KRAS Inhibitor Approved by FDA - NCI". www.cancer.gov. 2021-06-25. Retrieved 2023-12-09.
  4. Dhillon, Sohita (February 2023). "Adagrasib: First Approval". Drugs. 83 (3): 275–285. doi:10.1007/s40265-023-01839-y. ISSN 1179-1950. PMID 36763320.
Categories:
K-Ras(G12C) inhibitor 6 Add topic